- Report
- August 2024
- 121 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Drug Pipelines
- July 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
Kalydeco is a drug used to treat cystic fibrosis, a genetic disorder that affects the central nervous system. It is a small molecule drug that works by correcting the defective protein that causes cystic fibrosis. Kalydeco is the first drug to treat the underlying cause of cystic fibrosis, and is approved for use in adults and children aged six and older. It is taken orally, and is available in tablet and liquid form.
Kalydeco is a relatively new drug, and the market is still developing. It is a niche market, with few competitors. The drug is expensive, and is only available in certain countries. However, it is expected to become more widely available in the future.
Companies in the Kalydeco market include Vertex Pharmaceuticals, which manufactures and markets the drug, and several generic drug manufacturers. Other companies involved in the market include distributors, wholesalers, and pharmacies. Show Less Read more